Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853606 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction
A Phase 3 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 3
- Development phase
- 712
- Enrollment target
NCT00853606 is a Phase 3 study that has completed, run by VIVUS. The registered enrollment target is 712 participants.
The verdict
NCT00853606, a Phase 3 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 712 participants
- Enrollment target
Study Summary
This open-label study is being conducted to evaluate the long-term safety, tolerability, and efficacy of avanafil in men with mild to severe erectile dysfunction. Approximately 400 subjects will be enrolled and treated with avanafil for up to 52 weeks.
Interventions
- DRUG avanafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 712 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853606
The ClinicalTrials.gov registry entry for NCT00853606 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 712 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which avanafil is the first listed.
NCT00853606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853606 about?
NCT00853606 is a clinical study titled "Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction". This open-label study is being conducted to evaluate the long-term safety, tolerability, and efficacy of avanafil in men with mild to severe erectile dysfunction. Approximately 400 subjects will be enrolled and treated with avanafil for up to 52 weeks.
What is the current status of trial NCT00853606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 712 participants. The study started on 2009-03. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00853606?
The interventions under investigation include: avanafil (DRUG).
Who is sponsoring clinical trial NCT00853606?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.